Nonsteroidal anti-inflammatory drugs and the risk of actinic keratoses and squamous cell cancers of the skin

Journal of the American Academy of Dermatology

Volumn 53, Issue 6, 2005, Pages 966-972

  Butler, Gregory J ^a   Neale, Rachel ^a   Green, Adèle C ^a   Pandeya, Nirmala ^a   Whiteman, David C ^a,b  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; DICLOFENAC; IBUPROFEN; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM;

ACTINIC KERATOSIS; ARTICLE; AUSTRALIA; CANCER EPIDEMIOLOGY; CANCER RISK; CASE CONTROL STUDY; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG USE; HUMAN; INTERVIEW; PHYSICIAN; PRIORITY JOURNAL; RANDOMIZATION; RISK ASSESSMENT; SKIN CARCINOMA; SQUAMOUS CELL CARCINOMA;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; FEMALE; HUMANS; KERATOSIS; MALE; PHOTOSENSITIVITY DISORDERS; RISK FACTORS; SKIN NEOPLASMS;

EID: 27944450087     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2005.05.049     Document Type: Article

References (30)

1. R. Flower What are all the things that aspirin does? BMJ 327 2003 572 573
2. E. Fosslien Molecular pathology of cyclooxygenase-2 in neoplasia Ann Clin Lab Sci 30 2000 3 21
3. S.Y. Buckman, A. Gresham, P. Hale, G. Hruza, J. Anast, and J. Masferrer COX-2 expression is induced by UVB exposure in human skin: implications for the development of skin cancer Carcinogenesis 19 1998 723 729
4. K. Muller-Decker, G. Reinerth, P. Krieg, R. Zimmermann, H. Heise, and C. Bayerl Prostaglandin-H-synthase isozyme expression in normal and neoplastic human skin Int J Cancer 82 1999 648 656
5. S.M. Fischer, H.H. Lo, G.B. Gordon, K. Seibert, G. Kelloff, and R.A. Lubet Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis Mol Carcinog 25 1999 231 240
6. M. Asgari, E. White, and M.-M. Chren Nonsteroidal anti-inflammatory drug use in the prevention and treatment of squamous cell carcinoma Dermatol Surg 30 2004 1335 1342
7. A. Green, G. Williams, R. Neale, V. Hart, D. Leslie, and P. Parsons Daily sunscreen application and betacarotene supplementation in prevention of basal-cell and squamous-cell carcinomas of the skin: a randomised controlled trial Lancet 354 1999 723 729
8. A. Green, G. Beardmore, V. Hart, D. Leslie, R. Marks, and D. Staines Skin cancer in a Queensland population J Am Acad Dermatol 19 1988 1045 1052
9. A. Green, D. Battistutta, V. Hart, D. Leslie, G. Marks, and G. Williams The Nambour Skin Cancer and Actinic Eye Disease Prevention Trial: design and baseline characteristics of participants Control Clin Trials 15 1994 512 522
10. R.E. Harris, R.T. Chlebowski, R.D. Jackson, D.J. Frid, J.L. Ascenseo, and G. Anderson Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women's Health Initiative Cancer Res 63 2003 6096 6101
11. T.L. Diepgen, and V. Mahler The epidemiology of skin cancer Br J Dermatol 146 Suppl 61 2002 1 6
12. T.S. Housman, S.R. Feldman, P.M. Williford, A.B. Fleischer Jr., N.D. Goldman, and J.M. Acostamadiedo Skin cancer is among the most costly of all cancers to treat for the Medicare population J Am Acad Dermatol 48 2003 425 429
13. C. Mathers, R. Penm, R. Sanson-Fisher, R. Carter, and E. Campbell Health system costs of cancer in Australia 1993-94: an analysis of costs, service use, incidence and mortality by type of cancer 1998 Australian Institute of Health and Welfare and National Cancer Control Initiative Canberra
14. M. Alam, and D. Ratner Cutaneous squamous-cell carcinoma N Engl J Med 344 2001 975 983
15. J.F. Dore, R. Pedeux, M. Boniol, M.C. Chignol, and P. Autier Intermediate-effect biomarkers in prevention of skin cancer IARC Sci Publ 154 2001 81 91
16. J.K. Rivers, J. Arlette, N. Shear, L. Guenther, W. Carey, and Y. Poulin Topical treatment of actinic keratoses with 3.0% diclofenac in 2.5% hyaluronan gel Br J Dermatol 146 2002 94 100
17. H. Britt, G. Miller, S. Knox, J. Charles, L. Valenti, and J. Henderson General practice activity in Australia 2002-03. (General Practice Series No. 14) 2003 Australian Institute of Health and Welfare Canberra
18. J.J. Wang, P. Mitchell, W. Smith, M. Gillies, and F. Billson Systemic use of anti-inflammatory medications and age-related maculopathy: the Blue Mountains Eye Study Ophthalmic Epidemiol 10 2003 37 48
19. Australian Bureau of Statistics National Health Survey: Use of Medications, Australia 1995 1999 Australian Bureau of Statistics Canberra
20. D.R. English, B.K. Armstrong, A. Kricker, M.G. Winter, P.J. Heenan, and P.L. Randell Demographic characteristics, pigmentary and cutaneous risk factors for squamous cell carcinoma of the skin: a case-control study Int J Cancer 76 1998 628 634
21. T.A. Wilgus, A.T. Koki, B.S. Zweifel, D.F. Kusewitt, P.A. Rubal, and T.M. Oberyszyn Inhibition of cutaneous ultraviolet light B-mediated inflammation and tumor formation with topical celecoxib treatment Mol Carcinog 38 2003 49 58
22. N. Arber, and R.N. DuBois Nonsteroidal anti-inflammatory drugs and prevention of colorectal cancer Curr Gastroenterol Rep 1 1999 441 448
23. C. Denkert, M. Kobel, S. Berger, A. Siegert, A. Leclere, and U. Trefzer Expression of cyclooxygenase 2 in human malignant melanoma Cancer Res 61 2001 303 308
24. G. Davies, L.A. Martin, N. Sacks, and M. Dowsett Cyclooxygenase-2 (COX-2), aromatase and breast cancer: a possible role for COX-2 inhibitors in breast cancer chemoprevention Ann Oncol 13 2002 669 678
25. J.E. Wolf Jr., J.R. Taylor, E. Tschen, and S. Kang Topical 3.0% diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses Int J Dermatol 40 2001 709 713
26. J.K. Rivers, and D.I. McLean An open study to assess the efficacy and safety of topical 3% diclofenac in a 2.5% hyaluronic acid gel for the treatment of actinic keratoses Arch Dermatol 133 1997 1239 1242
27. C. Nelson, D. Rigel, S. Smith, N. Swanson, and J. Wolf Phase IV, open-label assessment of the treatment of actinic keratosis with 3.0% diclofenac sodium topical gel (Solaraze) J Drugs Dermatol 3 2004 401 407
28. K. Gebauer, P. Brown, and G. Varigos Topical diclofenac in hyaluronan gel for the treatment of solar keratoses Australas J Dermatol 44 2003 40 43
29. S. Friis, H.T. Sorensen, J.K. McLaughlin, S.P. Johnsen, W.J. Blot, and J.H. Olsen A population-based cohort study of the risk of colorectal and other cancers among users of low-dose aspirin Br J Cancer 88 2003 684 688
30. H.T. Sorensen, S. Friis, B. Norgard, L. Mellemkjaer, W.J. Blot, and J.K. McLaughlin Risk of cancer in a large cohort of nonaspirin NSAID users: a population-based study Br J Cancer 88 2003 1687 1692